The objectives of this proposal are to immunophenotype and genotype human urinary bladder tumors, and to characterize existing and newly developed antibodies and molecular probes as potential tumor markers that may be of use in the diagnosis of bladder tumors, as well as to identify those of conceivable clinical value in predicting tumor behavior and response to therapy. We have focused our studies on exfoliated bladder epithelial cells to the characterization of markers to aid in early detection of tumor cells and monitoring patients affected with bladder cancer, assessing recurrence and/or progression. In addition, we have concentrated our analyses on human tumor tissues to the production and evaluation of prognostic factors aimed at determining the invasive/metastaticgenotype and phenotype of transitional cell carcinomas and their sensitivity to different therapeutic modalities, thus allowing the urologist and medical oncologist to tailor therapy.
The specific aims are: (1) To identify markers of neoplastic transformation in urothelial cells to aid in the diagnosis of bladder cancer. We are developing an approach to distinguish exfoliated bladder epithelial tumor cells from other normal cells, including normal urothelium and inflammatory elements. This strategy is based on the combination of morphologic evaluation, DNA content by image analysis, phenotypic profile using urothelium tumor-associated antigens (i.e. Lewis X, M344, 19A211 and autocrine motility factor), and molecular probing (gene loci on chromosomes 9 and 15, as well as H-ras mutations) on cytologic preparations of exfoliated bladder cells. (2) To determine early and late events in the process of tumor progression in human bladder cancer, assessing the sensitivity and specificity of well characterized antibodies and molecular probes to (a) growth factor/growth factor receptors; (b) enzymes of the metastatic cascade; (c) tumor suppressor genes; (d) aberrant expression of oncogenes; and (e) cell surface differentiation antigens, including blood group related determinants. (3) To analyze the value of new markers as predictors of response to therapy and clinical outcome. This will include assessment of micrometastatic dissemination in surgical cases, the role of the multidrug resistance gene encoded P-glycoprotein as a possible mechanism for treatment failure in patients treated with systemic M-VAC chemotherapy, and modulation of the immuneresponse and fucosylated molecules during intravesical BCG therapy. (4) To collaborate with network members, NCI representatives, and other basic and clinical researchers in creating and exerting approved joint proposals to elucidate pertinent questions regarding new markers and clinical protocols for the diagnosis, prognosis and treatment of bladder cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA047538-05
Application #
3549123
Study Section
Special Emphasis Panel (SRC (42))
Project Start
1988-04-10
Project End
1996-03-31
Budget Start
1993-04-01
Budget End
1994-03-31
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Rabbani, Farhang; Koppie, Theresa M; Charytonowicz, Elizabeth et al. (2007) Prognostic significance of p27Kip1 expression in bladder cancer. BJU Int 100:259-63
Orlow, I; Cordon-Cardo, C (2002) Evaluation of alterations in the tumor suppressor genes INK4A and INK4B in human bladder tumors. Methods Mol Biol 179:43-59
Juan, Gloria; Hernando, Eva; Cordon-Cardo, Carlos (2002) Separation of live cells in different phases of the cell cycle for gene expression analysis. Cytometry 49:170-5
Sanchez-Carbayo, Marta; Socci, Nicholas D; Charytonowicz, Elizabeth et al. (2002) Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62:6973-80
Hernando, E; Orlow, I; Liberal, V et al. (2001) Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer 95:223-7
Juan, G; Cordon-Cardo, C (2001) Intranuclear compartmentalization of cyclin E during the cell cycle: disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer. Cancer Res 61:1220-6
Albert, P S; McShane, L M; Shih, J H et al. (2001) Latent class modeling approaches for assessing diagnostic error without a gold standard: with applications to p53 immunohistochemical assays in bladder tumors. Biometrics 57:610-9
McShane, L M; Aamodt, R; Cordon-Cardo, C et al. (2000) Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 6:1854-64
Szijan, I; Orlow, I; Dalamon, V et al. (2000) Alterations in the retinoblastoma pathway of cell cycle control in parathyroid tumors. Oncol Rep 7:421-5
Orjuela, M; Castaneda, V P; Ridaura, C et al. (2000) Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development. Clin Cancer Res 6:4010-6

Showing the most recent 10 out of 66 publications